The Absence of Immunoreactivity for Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), but Not for TIMP-2, Protein Is Associated with a Favorable Prognosis in Aggressive Breast Carcinoma (original) (raw)
Article navigation
Case Reports| July 29 2005
aDepartments of Oncology and Radiotherapy,
Search for other works by this author on:
cPathology, Oulu University Hospital, Oulu, Finland
Search for other works by this author on:
Taina Turpeenniemi-Hujanen
aDepartments of Oncology and Radiotherapy,
Search for other works by this author on:
Oncology (2005) 68 (2-3): 196–203.
Abstract
Objectives: High tumor grade and lymph node positivity are associated with poor prognosis in breast carcinoma. Prognostic markers are used to define which patient groups benefit from different treatment modalities, some of which are potentially very toxic. Matrix metalloproteinases (MMPs) degrade the extracellular matrix, and type IV collagenases MMP-2 and -9 have been linked to invasive behavior of several malignancies. Tissue inhibitors of metalloproteinases (TIMPs) -1 and -2 inhibit their activity and are therefore considered to have an inhibitory effect on tumor progression. The role of TIMPs in progression of breast carcinoma is, however, still poorly known. Here the effect of TIMP-1 and -2 on survival was examined in lymph node-positive breast carcinoma patients. Methods: TIMP-1 or -2 was evaluated with avidin-biotin immunohistochemical staining from paraffin-embedded sections of primary breast carcinoma of 132 cases. Results: Positive staining for TIMP-1 and -2 was observed in 81 and 84% of the tumors respectively. TIMP-1 correlated to the grade of the tumor (p = 0.047). Absence of TIMP-1 protein correlated with favorable disease-specific survival of the patients with high-grade tumors. After 10 years of follow-up as high as 88% of patients with a grade 2–3, but TIMP-1-negative tumor were alive, when only 61% of the TIMP-1-positive cases in this group survived by that time (p = 0.03). Conclusion: Our results suggest that lack of TIMP-1 protein expression is associated with a favorable prognosis in patients with node-positive high-grade breast carcinoma.
References
Tryggvason K, Höyhtyä M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209–218.
Chambers AF, Matrisian LM: Changing view of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260–1270.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135–1149.
Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153–1162.
Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270–1275.
Hirvonen R, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in T1–2N0 breast carcinoma. Breast Cancer Res Treat 2003;77:85–91.
Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 1993;59:329–341.
Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111–122.
Hayakawa T, Yamashita K, Kishi J, Harigaya K: Tissue inhibitor of metalloproteinases from human bone marrow stromal cell line KM 102 has erythroid-potentiating activity, suggesting its possible bifunctional role in the hematopoietic microenvironment. FEBS Lett 1990;268:125–128.
Stetler-Stevenson WG, Bersch N, Golde DW: Tissue inhibitor of metalloproteinase 2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992;296:231–234.
Hermanek P, Sobin LH (eds): UICC TNM Classification of Malignant Tumours, ed 4, rev 2. Berlin, Springer-Verlag, 1992.
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957.
Kallakury BVS, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113–3119.
Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatis J, Keramopoulos A: Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients’ survival in breast cancer. Mod Pathol 2002;15:26–34.
Ross JS, Kaur P, Sheehan CE, Hugh BS, Fisher AG, Kaufman RA Jr, Kallakury BVS: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198–205.
Visscher DW, Höyhtyä M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R: Enhanced expression on tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994;59:339–344.
Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307–313.
Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994;56:500–505.
Hansen Ree A, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997;3:1623–1628.
Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in beningn and malignant breast lesions: An in situ hybridization study. Virchows Arch 1999;435:566–573.
McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N, Duffy MJ: High levels of tissue inhibitors of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;884:44–48.
Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T: Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer – TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311–1316.
Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495–503.
Luparello C, Avanzato G, Carella C, Pucci-Minafra I: Tissue inhibitor of metalloproteinase (TIMP-1) and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235–244.
Inoue H, Mimore K, Shiraishi T, Kataoka A, Sadanaga N, Ueo H, Barnard GF, More M: Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol Rep 2000;7:871–874.
Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H: Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003;105:340–346.
Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O’Higgins N, Foidart JM, Duffy MJ: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118–121.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 